Chemical Properties:
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moistureManufacturer Supply Related Intermediates: Sodium Methanesulfinate CAS 20277-69-4 2-Aminoethyl Methyl Sulfone Hydrochloride CAS 104458-24-4 6-Iodo-4-Hydroxyquinazoline CAS 16064-08-7 5-[4-[3-Chloro-4-(3-Fluorobenzyloxy)anilino]-6-Quinazolinyl]furan-2-Carboxaldehyde CAS 231278-84-5 CAS 231277-92-2 CAS 388082-77-7| Item | Specifications |
| Appearance | Almost White or Light Yellow Crystalline Powder |
| Identification | IR; HPLC |
| Purity / Analysis Method | ≥99.5% (HPLC) |
| Melting Point | 141.0~149.0℃ |
| Loss on Drying | ≤0.50% |
| Residue on Ignition | ≤0.10% |
| Heavy Metals (as Pb) | ≤20ppm |
| Organic Volatile Impurities | Meet the Requirement |
| Related Substances | |
| Single Impurity | ≤0.30% |
| Total Impurities | ≤0.50% |
| Test Standard | Enterprise Standard |
| Shelf Life | 2 Years When Properly Stored |
| Usage | API, An Oral Treatment for Breast Cancer |
Description:
Specifications:
Package & Storage:
| Chemical Name | N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-[[(2-(methylsulfonyl)ethyl]amino]methyl]furan-2-yl]quinazolin-4-amine |
| Synonyms | N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine |
| CAS Number | 231277-92-2 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C29H26ClFN4O4S |
| Molecular Weight | 581.06 |
| Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
API (CAS: 231277-92-2) is a targeted therapy of breast cancer drug, is a tyrosine kinase inhibitor, can effectively inhibit the human epidermal growth factor receptor -1 (ErbB1) and human epidermal growth factor receptor (ErbB2) tyrosine kinase activity of -2. It is unique in that it can play a role in a variety of ways, so that breast cancer cells can not receive the signal needed for growth. The mechanism of action is to inhibit the intracellular EGFR (ErbB-1) and HER2 (ErbB-2) ATP sites to prevent phosphorylation and activation of tumor cells, and to block the down-regulation of signaling by EGFR (ErbB-1) and HER2 (ErbB-1) homogeneous and heterogeneous two aggregates. The combination of (CAS: 231277-92-2) with Capecitabine is used to treat patients with advanced or metastatic breast cancer with overexpression of human epidermal receptor2, already treated with anthracyclines, paclitaxel, and trastuzumab. Clinical trials have shown that it also effectively treats HER2-type cancer patients with Herceptin resistance.
